- Q1 2024 Agenus Inc Earnings Call TranscriptMay 07, 2024$12.01 (-7.26%)Earnings
- Q4 2023 Agenus Inc Earnings Call and Corporate Update TranscriptMar 14, 2024$11.99 (-8.94%)Earnings
- Q3 2023 Agenus Inc Earnings Call and To Provide Corporate Update TranscriptNov 07, 2023$16.4 (+4.94%)Earnings
- Agenus Inc To Host Endpoints Webinar TranscriptOct 18, 2023
- Agenus Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Agenus Inc Earnings Call TranscriptMay 09, 2023$30 (-5.66%)Earnings
- Agenus Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Q4 2022 Agenus Inc Earnings Call TranscriptMar 14, 2023$35.13 (+4.68%)Earnings
- Agenus Inc at B Riley Securities Oncology Conference (Virtual) TranscriptJan 18, 2023
- Agenus Inc to Host “The Road Taken” R&D Event TranscriptNov 12, 2022
- Q3 2022 Agenus Inc Earnings Call TranscriptNov 08, 2022$43.77 (-6.69%)Earnings
- Q2 2022 Agenus Inc Earnings Call TranscriptAug 09, 2022$50.24 (-1.92%)Earnings
- Agenus Inc To Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress TranscriptJun 29, 2022
- Q1 2022 Agenus Inc Earnings Call TranscriptMay 10, 2022$32.58 (+9.21%)Earnings
- Q4 2021 Agenus Inc Earnings Call TranscriptMar 01, 2022$50.83 (-4.07%)Earnings
- Q3 2021 Agenus Inc Earnings Call TranscriptNov 09, 2021$87.34 (+6.46%)Earnings
- Agenus Inc Business Update Call TranscriptOct 22, 2021
- Q2 2021 Agenus Inc Earnings Call TranscriptAug 09, 2021$105.98 (-4.09%)Earnings
- Agenus Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Agenus Inc Discuss the Global Licensing Agreement Between Agenus and Bristol Myers Squibb - Corporate Call TranscriptMay 18, 2021
- Q1 2021 Agenus Inc Earnings Call TranscriptMay 06, 2021$55.35 (-4.24%)Earnings
- Q4 2020 Agenus Inc Earnings Call TranscriptMar 15, 2021$66.73 (+2.72%)Earnings
- Agenus Inc. - Special Call TranscriptFeb 11, 2021
- Agenus Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 17, 2020
- Q3 2020 Agenus Inc Earnings Call TranscriptOct 29, 2020$73.01 (+0.81%)Earnings
- Agenus Inc. - Special Call TranscriptSep 21, 2020
- Q2 2020 Agenus Inc Earnings Call TranscriptAug 06, 2020$64.96 (-0.90%)Earnings
- Agenus Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Agenus Inc. - Special Call TranscriptJun 02, 2020
- Q1 2020 Agenus Inc Earnings Call TranscriptMay 07, 2020$49.85 (-3.79%)Earnings
- Q4 2019 Agenus Inc Earnings Call TranscriptMar 12, 2020$51.22 (-4.04%)Earnings
- Agenus Inc Corporate Analyst Meeting TranscriptFeb 20, 2020
- Agenus Inc. - Special Call TranscriptNov 15, 2019
- Q3 2019 Agenus Inc Earnings Call TranscriptNov 04, 2019$60.25 (+7.72%)Earnings
- Q2 2019 Agenus Inc Earnings Call TranscriptAug 08, 2019$51.03 (+18.72%)Earnings
- Agenus Inc Annual Shareholders Meeting TranscriptJun 19, 2019
- Q1 2019 Agenus Inc Earnings Call TranscriptMay 09, 2019$56.52 (+8.27%)Earnings
- Q4 2018 Agenus Inc Earnings Call TranscriptMar 14, 2019$58.68 (+1.01%)Earnings
- Agenus Inc. - Special Call TranscriptFeb 19, 2019
Agenus Inc. - Special Call Transcript
Hi, everyone, and welcome to our first R&D update, which is coined Agenus Insights.
There's never been a more important time in the history of cancer therapy. Technology, partnered with genomic and proteomic insights have accelerated our pace of drug discovery to speeds that have never been seen before. Agenus is at the forefront of this, with more than 15 new discoveries advancing in the clinic in just the past 4 years. A few of those first agents are in route to BLA with filings already underway.
Our anti-PD-1 is delivering differentiated activity compared to commercially available PD-1 antibodies. And 1181, our Fc-engineered anti-CTLA-4, we presented a data update yesterday, and that molecule is producing very exciting results in difficult-to-treat tumors.
Now TIGIT, the topic of our conversation today. It's shaping up as the next breakthrough target in I-O. And only as recently as last year, anti-CTLA-4 and anti-PD-1 were the only validated immunotherapy combinations for patients with cancer. Today, this third pathway
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)